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Background. We investigated the performance of polymerase chain reaction (PCR) on blood in the diagnosis of pneumococcal 
pneumonia among children from 7 low- and middle-income countries.
Methods. We tested blood by PCR for the pneumococcal autolysin gene in children aged 1–59 months in the Pneumonia 
Etiology Research for Child Health (PERCH) study. Children had World Health Organization–defined severe or very severe pneu-
monia or were age-frequency–matched community controls. Additionally, we tested blood from general pediatric admissions in 
Kilifi, Kenya, a PERCH site. The proportion PCR-positive was compared among cases with microbiologically confirmed pneumo-
coccal pneumonia (MCPP), cases without a confirmed bacterial infection (nonconfirmed), cases confirmed for nonpneumococcal 
bacteria, and controls.
Results. In PERCH, 7.3% (n = 291/3995) of cases and 5.5% (n = 273/4987) of controls were blood pneumococcal PCR-positive (P < 
.001), compared with 64.3% (n = 36/56) of MCPP cases and 6.3% (n = 243/3832) of nonconfirmed cases (P < .001). Blood pneumococ-
cal PCR positivity was higher in children from the 5 African countries (5.5%–11.5% among cases and 5.3%–10.2% among controls) than 
from the 2 Asian countries (1.3% and 1.0% among cases and 0.8% and 0.8% among controls). Among Kilifi general pediatric admis-
sions, 3.9% (n = 274/6968) were PCR-positive, including 61.7% (n = 37/60) of those with positive blood cultures for pneumococcus.
Discussion. The utility of pneumococcal PCR on blood for diagnosing childhood pneumococcal pneumonia in the 7 low- and 
middle-income countries studied is limited by poor specificity and by poor sensitivity among MCPP cases.
Keywords. pneumonia; pneumococcus; PCR; blood; diagnosis.
 
Microbiological confirmation of childhood pneumococcal 
pneumonia is difficult. A  minority of cases are detected by 
blood culture even under ideal conditions [1]; sputum is not 
spontaneously produced by young children and can be con-
taminated by organisms carried in the nasopharynx; detection 
of pneumococcus in the nasopharynx may represent asympto-
matic carriage; diagnostic serology is insensitive in children, 
and paired samples are difficult to obtain [2]; and urinary 
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antigen tests are not sufficiently specific for use in young chil-
dren [3, 4].
The development of molecular tools to diagnose pneumo-
coccal disease has been slow. Some earlier gene targets were 
found to be nonspecific to Streptococcus pneumoniae due to 
its close homology with related noninvasive species [5–9]. 
Consequently, pneumococcal polymerase chain reaction (PCR) 
assays now commonly target the autolysin gene (lytA), which 
is regarded as more specific [9]. However, clinical specificity of 
this assay has been difficult to measure, particularly among chil-
dren, the population who most need an improved diagnostic 
test. Two studies found no PCR-positive blood samples using 
lytA-targeted assays among healthy children, suggesting 100% 
specificity [4, 10].
We investigated the performance of pneumococcal PCR on 
blood specimens for diagnosing pneumococcal pneumonia in 
children from low- and middle-income countries as part of the 
Pneumonia Etiology Research for Child Health (PERCH) study.
METHODS
PERCH Participants
PERCH enrolled children aged 1–59 months from August 2011 
to January 2014 (24 months at each site) at 9 study sites across 7 
countries: Dhaka and Matlab, Bangladesh; Basse, The Gambia; 
Kilifi, Kenya; Bamako, Mali; Soweto, South Africa; Nakhon 
Phanom and Sa Kaeo, Thailand; and Lusaka, Zambia. Cases 
were hospitalized with World Health Organization (WHO)–
defined severe or very severe pneumonia, and controls with-
out case-defining pneumonia were randomly selected from the 
community. Controls were frequency matched to cases within 
the following age groups: 1 to <6 months, 6 to <12 months, 12 to 
<24 months, and 24 to <60 months. Identification and selection 
of cases and controls have been described previously [11].
Kilifi General Pediatric Admissions
The Kenya site also evaluated children aged ≤14  years not 
enrolled in the PERCH study who were admitted to the general 
medical pediatric service at Kilifi County Hospital (KCH) from 
December 2010 until December 2013. The definition of pneu-
monia severity was the same as that used in the PERCH study, 
except that lower chest wall indrawing was not a requirement 
for children aged >5 years. Supplementary Figure 1 describes 
the population of Kilifi general pediatric admissions studied; 
all such children were offered admission blood tests, including 
blood cultures.
Laboratory and Radiological Methods
Blood for PCR was collected at admission from both PERCH 
cases and KCH general admissions cases, alongside blood for 
culture, and from PERCH controls at enrollment. Blood sam-
ples for PCR were collected into dedicated ethylenediamine-
tetraacetic acid tubes. Detailed methods for the processing of 
PERCH samples can be found elsewhere in this supplement 
[12]. For the additional KCH children, 200 μL of whole blood 
was extracted by the manual spin-column method using the 
QIAamp DNA blood mini kit within a week of sample collec-
tion. Extracted DNA was frozen at −80°C until it underwent 
pneumococcal PCR.
Whole blood was evaluated for the presence of S. pneumo-
niae nucleic acid using a quantitative real-time PCR assay for 
the lytA gene based on the US Centers for Disease Control and 
Prevention (CDC) method [9].
Blood cultures were performed as described previously at all 
PERCH sites [12].
Nasopharyngeal swabs for pneumococcal culture and 
nasopharyngeal/oropharyngeal (NP/OP) swabs for res-
piratory pathogen multiplex PCR were collected from all 
cases and controls in PERCH and from those KCH general 
admissions cases meeting the WHO definition of severe or 
very severe pneumonia. Quantitative real-time PCR for res-
piratory pathogens was performed on NP/OP specimens, as 
described elsewhere [12].
In PERCH, lung aspirates were collected at select sites (The 
Gambia, South Africa, Mali, and Bangladesh), and pleural fluid 
was collected from cases when clinically indicated at all sites.
Among KCH general admission patients, cerebrospinal fluid 
(CSF) was collected from children with clinical suspicion of 
meningitis and from neonates with WHO-defined probable 
severe bacterial illness and cultured for bacterial and fungal 
pathogens using standard microbiological methods.
All PERCH laboratory assays were performed in the individ-
ual site laboratories in each country, with standardized quality 
control procedures and regular external quality assurance [12].
Chest radiographs (CXRs) were obtained from PERCH cases 
at enrollment and classified as consolidation, other infiltrate, 
both consolidation and other infiltrate, normal, or uninterpret-
able by a trained panel of radiologists and pediatricians [13, 
14]. Chest radiographs from non-PERCH KCH children were 
obtained from those with pneumonia; results were reported 
from those interpreted according to WHO methods [13]. More 
non-PERCH CXRs became available after March 2012 when a 
mobile CXR unit was procured.
Definitions
Microbiologically confirmed pneumococcal pneumonia 
(MCPP) PERCH cases had pneumococcus detected by blood 
culture; culture, antigen detection, or PCR of pleural fluid; or 
culture or PCR of lung aspirate. Cases confirmed for a non-
pneumococcal bacterial infection had a positive culture of 
blood, lung aspirate, or pleural fluid, or PCR of lung aspirate 
or pleural fluid, for a pathogenic bacterium other than pneu-
mococcus. Nonconfirmed cases had no bacterial pathogen 
detected by blood culture; culture, antigen detection, or PCR of 
pleural fluid; or culture or PCR of lung aspirate.
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Pneumococcal conjugate vaccine (PCV) vaccinated was 
defined as having received at least 1 dose of vaccine.
Receipt of antibiotics prior to specimen collection was 
defined by having either a positive serum bioassay [12] or doc-
umented administration of antibiotics on the day of admission 
at the referral or study hospital prior to blood culture collection.
Human immunodeficiency virus (HIV) infection was defined 
in PERCH as detectable viral load or presence of HIV antibod-
ies by serology (for children aged >12 months). In Kilifi, HIV 
antibody/antigen rapid immunochromatographic test results as 
per the Kenyan national scheme were used.
High-density pneumococcal NP/OP PCR density was 
defined as >6.9 log10 copies/mL [15].
A PERCH control was considered to have a respiratory tract 
illness if cough or runny nose were reported. Respiratory tract 
illness was also considered present if the child had (1) ear dis-
charge, wheeze, or difficulty breathing, and (2) either fever 
(temperature ≥38.0°C or reported fever in the past 48 hours) or 
sore throat. No control satisfied the WHO criteria for severe or 
very severe pneumonia.
Analysis
The proportion of blood samples positive by pneumococcal 
PCR was studied by clinical and laboratory characteristics. 
PERCH analyses were conducted overall and stratified by 
site and by case and control status. Site-specific analyses were 
performed using the chi-square or Fisher’s exact test. PERCH 
analyses with all sites combined were performed using logis-
tic regression adjusted for PERCH site. Characteristics asso-
ciated with whole-blood pneumococcal PCR positivity were 
evaluated among case and control groups at sites with at least 
1 blood pneumococcal PCR-positive in that group. Logistic 
regression models used the Firth modified likelihood approach 
to minimize bias due to small sample size and to accommodate 
zero-frequency cells [16].
As part of a quality control process, the proportion of pneu-
mococcal PCR-positive samples was examined over time by 
date of sample collection, date of DNA extraction, and date of 
PCR test for each site.
All PERCH analyses were performed using SAS 9.4; data 
were from the July 2015 PERCH data freeze. Analyses of the 
additional data from Kilifi were performed using STATA 13.1.
ETHICAL CONSIDERATIONS
The PERCH study protocol was approved by the institutional 
review board or ethical review committee at each of the study 
site institutions and at The Johns Hopkins Bloomberg School 
of Public Health. The analysis of additional participants at the 
Kilifi site was approved by the ethical review committee at the 
Kenya Medical Research Institute. Parents or guardians of all 
participants provided written informed consent.
RESULTS
PERCH Study
In PERCH, whole-blood PCR results were available from 
94.4% (n  =  3995/4232) cases and 93.7% (n  =  4987/5325) 
controls; 7.3% of cases and 5.5% of controls were PCR-
positive for pneumococcus in blood (P  <  .001). Sensitivity 
among pneumococcal blood culture–positive cases was 
68.2% (n  =  30/44) and among MCPP cases was 64.3% 
(n  =  36/56). Positivity among nonconfirmed cases (6.3%) 
and CXR-positive nonconfirmed cases (7.3%) was lower 
than among MCPP cases (P  <  .001) and cases confirmed 
for a nonpneumococcal bacterium (n  =  12/107: 11.2%; 
P = .07 and P = .02, respectively) (Table 1 and Supplementary 
Table 1).
Positive blood pneumococcal PCR findings were observed at 
all sites among both cases and controls, including controls with-
out respiratory tract illness; 2 sites (Kenya and South Africa) 
observed higher positivity in controls than in cases (Figure  1 
and Supplementary Table 1). Blood pneumococcal PCR posi-
tivity was higher at the African sites (range, 5.5%–11.5% among 
cases and 5.3%–10.2% among controls) than at the 2 Asian 
sites (1.3% and 1.0% among cases and 0.8% and 0.8% among 
controls).
No association was found between pneumococcal PCR 
positivity in blood and age or sex. Blood pneumococcal PCR 
positivity tended to be higher overall among cases with HIV 
infection (Table 1 and Supplementary Tables 2–8). Among the 
4 African sites that introduced PCV prior to PERCH, PCV use 
was associated with blood pneumococcal PCR positivity only 
in South Africa, where pneumococcal PCR positivity was lower 
among vaccinated versus unvaccinated cases (5.4% vs 9.5%; P 
= .04). No meaningful association with prior antibiotic use was 
observed.
Among both cases (7.4% vs 3.0%; P < .01) and controls 
(5.9% vs 3.7%; P = .02), blood pneumococcal PCR positiv-
ity was higher with versus without pneumococcus detected 
in the nasopharynx as measured by culture or PCR (Table 1). 
A quantitative nasopharyngeal PCR result above a threshold 
of 6.9 log10 copies/mL was significantly associated with blood 
pneumococcal PCR positivity among cases but not controls. 
The association between nasopharyngeal carriage and blood 
pneumococcal PCR positivity varied by site (Supplementary 
Tables 2–8).
Among nonconfirmed cases, higher proportions of blood 
pneumococcal PCR positivity were also observed for clinical 
findings typically associated with pneumococcal pneumonia: 
CXR-positive cases had higher positivity than CXR-negative 
cases (7.3% vs 5.4%; P = .05), with even higher positivity in 
the subset with consolidation on CXR (9.7%). This was also 
true in cases with C-reactive protein (CRP) ≥40 mg/L versus 
<40 mg/L (10.0% vs 4.8%; P < .001) (Table 1). Site-specific 
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Table 1. Characteristics Associated With Whole-Blood Pneumococcal Polymerase Chain Reaction Positivity in PERCH, by Case and Control Groups
All MCPP Casesa Nonconfirmed Casesb
Confirmed Nonpneumococcal 
Bacterial Casesc All Controls
No. No. (%) WB+ aORd No. No. (%) WB+ aOR No. No. (%) WB+ aOR No. No. (%) WB+ aOR
Overall 56 36 (64.3) ... 3832 243 (6.3) ... 98 12 (12.2) ... 4987 273 (5.5) ...
PERCH site
 Kenya 4 3 (75.0) ... 556 25 (4.5) ... 6 3 (50.0) ... 751 48 (6.4) ...
 The Gambia 16 6 (37.5) ... 570 51 (8.9) ... 16 4 (25.0) ... 608 47 (7.7) ...
 Mali 24 19 (79.2) ... 619 56 (9.0) ... 26 2 (7.7) ... 715 38 (5.3) ...
 Zambia 7 4 (57.1) ... 494 37 (7.5) ... 23 2 (8.7) ... 603 31 (5.1) ...
 South Africa 5 4 (80.0) ... 885 66 (7.5) ... 27 1 (3.7) ... 963 98 (10.2) ...
 Thailand 0 0 (0) ... 218 3 (1.4) ... 0 0 (0) ... 622 5 (0.8) ...
 Bangladesh 0 0 (0) ... 490 5 (1.0) ... 0 0 (0) ... 725 6 (0.8) ...
Age ... P = .92 ... ... P = .12 ... ... P = .44 ... ... P = .85 ...
 1–5 mo 11 7 (63.6) ... 1570 96 (6.1) ... 40 3 (7.5) ... 1534 88 (5.7) ...
 6–11 mo 14 10 (71.4) 1.3 869 68 (7.8) 1.46 27 3 (11.1) 1.25 1195 72 (6.0) 1.14
 12–23 mo 17 9 (52.9) 0.76 854 52 (6.1) 1.27 19 3 (15.8) 2.46 1218 64 (5.3) 1.11
 24–59 mo 14 10 (71.4) 0.83 539 27 (5.0) 1.06 12 3 (25.0) 4.35 1040 49 (4.7) 1.01
Sex ... P = .28 ... ... P = .36 ... ... P = .80 ... ... P = .09 ...
 Female 27 21 (77.8) 2.01 1614 98 (6.1) 0.88 58 8 (13.8) 1.18 2491 150 (6.0) 1.24
 Male 29 15 (51.7) ... 2218 145 (6.5) ... 40 4 (10.0) ... 2495 123 (4.9) ...
HIV infected ... P = .89 ... ... P = .03 ... ... P = .02 ... ... P = .66 ...
 Yes 13 10 (76.9) 1.14 211 24 (11.4) 1.7 13 3 (23.1) 10.1 208 19 (9.1) 1.12
 No 36 23 (63.9) ... 3299 198 (6.0) ... 75 8 (10.7) ... 4224 224 (5.3) ...
PCV vaccinatede ... P = .36 ... ... P = .63 ... ... P = .66 ... ... P = .07 ...
 Yes 37 22 (59.5) 0.44 1949 142 (7.3) 0.92 49 6 (12.2) 1.55 2447 196 (8.0) 1.51
 No 11 9 (81.8) ... 574 48 (8.4) ... 20 1 (5.0) ... 473 24 (5.1) ...
Very severe pneumonia ... P = .13 ... ... P = .23 ... ... P = .84 ... ... ... ...
 Yes 32 23 (71.9) 2.73 1213 90 (7.4) 1.19 47 6 (12.8) 0.88 0 0 (0) ...
 No 24 13 (54.2) ... 2619 153 (5.8) ... 51 6 (11.8) ... 0 0 (0) ...
Prior antibiotic usef ... P = .92 ... ... P = .681 ... ... P = .45 ... ... P = .25 ...
 Yes 14 9 (64.3) 1.08 1504 100 (6.6) 1.07 49 5 (10.2) 1.74 111 9 (8.1) 1.5
 No 40 25 (62.5) ... 2166 132 (6.1) ... 47 6 (12.8) ... 4582 253 (5.5) ...
NP culture positive for 
pneumococcus
... P = .52 ... ... P = .002 ... ... P = .51 ... ... P = .01 ...
 Yes 44 28 (63.6) 1.74 2000 149 (7.5) 1.55 40 5 (12.5) 0.62 3420 205 (6.0) 1.46
 No 11 7 (63.6) ... 1788 91 (5.1) ... 55 6 (10.9) ... 1518 63 (4.2) ...
Pneumococcus colo-
nized (culture or PCR 
positive)
... ... ... ... P ≤ .001 ... ... P = .18 ... ... P = .02 ...
 Yes 54 35 (64.8) ... 2882 214 (7.4) 2.33 68 11 (16.2) 6.42 4042 238 (5.9) 1.57
 No 0 0 (0) ... 897 27 (3.0) ... 26 0 (0.0) ... 908 34 (3.7) ...
Pneumococcal NP/OP 
PCR density >6.9 
log10 copies/mL
... P = .10 ... ... P = .002 ... ... P = .69 ... ... P = .32 ...
 Yes 36 26 (72.2) 3.62 457 48 (10.5) 1.69 27 3 (11.1) 0.74 392 27 (6.9) 1.24
 No 18 9 (50.0) ... 3306 192 (5.8) ... 68 8 (11.8) ... 4490 243 (5.4) ...
NP/OP PCR positive for 
any virus
... P = .56 ... ... P = .15 ... ... P = .63 ... ... P = .50 ...
 Yes 51 32 (62.7) 0.32 3353 207 (6.2) 0.75 79 8 (10.1) 0.67 3853 211 (5.5) 1.11
 No 3 3 (100) ... 414 33 (8.0) ... 16 3 (18.8) ... 1034 59 (5.7) ...
Hypoxemiag ... P = .13 ... ... P = .89 ... ... P = .48 ... ... -- ...
 Yes 23 19 (82.6) 2.9 1446 102 (7.1) 0.98 50 4 (8.0) 0.62 NA NA NA
 No 33 17 (51.5) ... 2377 141 (5.9) ... 47 8 (17.0) ... NA NA NA
Died in hospital ... P = .30 ... ... P = .85 ... ... P = .38 ... ... ... ...
 Yes 13 10 (76.9) 2.26 240 19 (7.9) 1.05 31 5 (16.1) 1.76 NA NA NA
 No 43 26 (60.5) ... 3590 224 (6.2) ... 67 7 (10.4) ... NA NA NA
CXR+h ... P = .11 ... ... P = .05 ... ... P = .39 ... ... ... ...
 Yes 38 21 (55.3) 0.07 1745 127 (7.3) 1.33 50 8 (16.0) 2.01 NA NA NA
 No 6 6 (100) ... 1525 82 (5.4) ... 26 2 (7.7) ... NA NA NA
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Figure 1. Proportion positive for pneumococcal whole-blood polymerase chain reaction (PCR), by PERCH site and case or control group. Microbiologically confirmed 
pneumococcal pneumonia (MCPP) cases were defined as isolation of pneumococcus from blood culture; culture or PCR of lung aspirate or pleural fluid; or BinaxNOW antigen 
detection on pleural fluid. Nonconfirmed cases were defined as cases without isolation of bacteria from culture of blood, lung aspirate, or pleural fluid, or PCR of lung aspirate 
or pleural fluid. Confirmed nonpneumococcal bacterial cases were defined as isolation of another bacteria from culture of blood, lung aspirate, or pleural fluid, or PCR of lung 
aspirate or pleural fluid. Chest X-ray–positive (CXR+) was defined as radiographic evidence of pneumonia (consolidation and/or other infiltrates). See Supplementary Table 
1 with numeric results for each site and case/control group. P values from Fisher’s exact or chi-square test for difference in whole blood–positivity by site: MCPP: P = .08; 
nonconfirmed: P < .001; nonconfirmed CXR+: P < .001; confirmed nonpneumococcus bacterial case: P = .04; all controls: P < .001; controls with respiratory tract illness: P < .001; 
controls without acute respiratory illness: P < .001. Abbreviations: AC, alveolar consolidation; BCX+, blood culture positive; CXR, chest radiograph; MCPP, microbiologically 
confirmed pneumococcal pneumonia; PERCH, Pneumonia Etiology Research for Child Health; pneu, pneumococcus; RTI, controls with respiratory tract illness.
All MCPP Casesa Nonconfirmed Casesb
Confirmed Nonpneumococcal 
Bacterial Casesc All Controls
No. No. (%) WB+ aORd No. No. (%) WB+ aOR No. No. (%) WB+ aOR No. No. (%) WB+ aOR
Alveolar consolidation 
on CXR
... P = .43 ... ... P ≤ .001 ... ... P = .81 ... ... ... ...
 Yes 31 18 (58.1) 0.55 853 83 (9.7) 1.81 35 5 (14.3) 1.18 NA NA NA
 No 13 9 (69.2) ... 2417 126 (5.2) ... 41 5 (12.2) ... NA NA NA
WBC >15/mm3 ... P = .27 ... ... P = .93 ... ... P = .02 ... ... ... ...
 Yes 27 15 (55.6) 0.49 1383 81 (5.9) 0.99 40 2 (5.0) 0.13 NA NA NA
 No 27 19 (70.4) ... 2277 148 (6.5) ... 54 10 (18.5) ... NA NA NA
CRP ≥40mg/L ... P = .25 ... ... P ≤ .001 ... ... P = .58 ... ... ... ...
 Yes 40 26 (65.0) 2.96 873 87 (10.0) 1.87 58 5 (8.6) 0.63 NA NA NA
 No 8 3 (37.5) ... 2456 119 (4.8) ... 25 2 (8.0) ... NA NA NA
Characteristics associated with whole-blood pneumococcal polymerase chain reaction positivity were evaluated among case and control groups at sites with at least 1 blood pneumococcal 
PCR-positive in that group. P value for association of study group with whole blood–positivity in a logistic regression model adjusted for site: microbiologically confirmed pneumococcal 
pneumonia (MCPP) versus nonconfirmed: P < .001; MCPP versus all controls: P < .001; MCPP versus confirmed nonpneumococcal bacterial cases P < .001; nonconfirmed versus all con-
trols: P = .63; nonpneumococcal bacterial case versus all controls: P = .04. Bold indicates P < .05.
Abbreviations: aOR, adjusted odds ratio; CRP, C-reactive protein; CXR, chest radiograph; HIV, human immunodeficiency virus; MCPP, microbiologically confirmed pneumococcal pneumonia; 
NA, not applicable; NP, nasopharyngeal; OP, oropharyngeal; PCR, polymerase chain reaction; PCV, pneumococcal conjugate vaccine; PERCH, Pneumonia Etiology Research for Child Health; 
WB, whole blood; WBC, white blood cells. 
aMCPP was defined as isolation of pneumococcus from blood culture; culture or PCR of lung aspirate or pleural fluid; or BinaxNOW antigen detection on pleural fluid.
bNonconfirmed cases were defined as cases without isolation of bacteria from culture of blood, lung aspirate, or pleural fluid, or PCR of lung aspirate or pleural fluid.
cConfirmed nonpneumococcal bacterial case was defined as a case with any nonpneumococcal bacterial pathogen detected by blood culture, by lung aspirate culture or PCR, or by pleural 
fluid culture or PCR.
dAdjusted for site.
ePCV vaccinated defined as at least 1 dose. Restricted to PCV-using sites (Kenya, The Gambia, Mali, and South Africa).
fPrior use of antibiotics defined as serum bioassay positive, antibiotic administration at the referral facility, or antibiotic administration prior to blood specimen collection at the study facility.
gHypoxemia was defined as <92% on room air (<90% at elevation, Zambia and South Africa) or a requirement for supplemental oxygen if a room air reading was not available.
hCXR+ defined as radiographic evidence of pneumonia (consolidation and/or other infiltrates).
Table 1. Continued
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exceptions for association with CXR and CRP findings can be 
seen (Supplementary Tables 2–8). Analyses restricted to the 
CXR-positive nonconfirmed group were similar to analyses 
of the entire nonconfirmed case group (data not shown). The 
prevalence of pneumococcal PCR positivity in blood was also 
significantly higher among nonconfirmed cases with positive 
CXR (7.3%) or CRP ≥ 40 mg/L (10.0%) than among controls 
(5.5%; P < .01 for each comparison).
Low oxygen saturation, an elevated white blood cell count, 
and death in hospital were not significantly associated with 
blood pneumococcal PCR positivity overall or at any site.
Kilifi General Pediatric Admissions
Of 6968 blood specimens collected from non-PERCH gen-
eral pediatric admissions in Kilifi, 274 (3.9%) were whole-
blood pneumococcal PCR-positive. Pneumococcal PCR in 
blood was positive among 61.7% (n = 37/60) of blood cul-
ture–positive cases and among 60.9% (n = 39/64) of blood 
culture– or CSF culture–positive cases. Among children least 
likely to have pneumococcal disease—those with a pathogen 
other than pneumococcus by culture of blood or CSF—4.7% 
(n = 7/148) were positive for pneumococcal PCR on blood, 
which was similar to the percentage observed in children 
with nonbacteremic pneumonia (4.2%) (Supplementary 
Table 9).
Neonates were the least likely to be pneumococcal PCR-
positive in blood (2.1%; n = 29/1379), compared with chil-
dren aged 29 days–59 months (4.3%; n = 177/4148) and 
children aged >59 months (4.7%; n = 68/1441; P = .003) 
(Table 2).
Table 2 and Table 3 describe characteristics associated with 
blood pneumococcal PCR positivity among children aged 
<5 years (Table 2) and aged 5–14 years (Table 3). Among chil-
dren who did not have pneumococcal bacteremia and who did 
not have CSF collected, pneumonia status was associated with 
a positive pneumococcal blood PCR, with 4.2% of children 
aged 1–59  months with WHO-defined severe or very severe 
pneumonia positive compared with 2.7% without (P  =  .03). 
Clinical characteristics associated with blood pneumococcal 
PCR positivity among both children aged 1–59  months and 
children aged ≥60  months included HIV antibody positivity, 
nasopharyngeal pneumococcal carriage, and radiologically 
confirmed pneumonia. Children <60 months of age who died 
in hospital were more likely to have been blood pneumococcal 
PCR-positive than survivors (Table 2); this was not the case for 
older children (Table 3).
Assay Quality Control
Whole-blood pneumococcal PCR positivity was evaluated at 
each PERCH site over time, by date of sample collection, date 
of DNA extraction, and date of PCR testing, and no obvious 
trends in positivity were detected (Supplementary Figure 2–4).
DISCUSSION
Pneumococcal PCR on blood was positive among 1%–10% of 
community controls in 7 African and Asian countries and is 
therefore not 100% specific for the diagnosis of pneumococcal 
disease as has been previously reported [4, 10]. The utility of 
pneumococcal PCR on blood in diagnosing childhood pneu-
mococcal pneumonia is further limited by the fact that posi-
tivity among controls (5.5%) was similar to that in pneumonia 
cases not confirmed for any bacterial pathogen (6.3%), pos-
itivity among cases confirmed for nonpneumococcal bacteria 
(11.2%) was greater than that among nonconfirmed cases, and 
sensitivity among MCPP cases was low (64.3%).
There was a clear difference in the detection of pneumococ-
cus in blood by PCR between the African and the Asian PERCH 
sites, with only 1.1% of nonconfirmed cases being pneumo-
coccal PCR-positive at the Asian sites, compared with 7.5% 
at the African sites, and no MCPP cases in the Asian PERCH 
sites, despite common nasopharyngeal pneumococcal carriage 
among Thailand (57%) and Bangladesh (72%) cases. The reason 
for these differences between African and Asian sites is unclear, 
although it could be due to differences in transmission dynam-
ics, host susceptibility, or prehospital antibiotic use. Other stud-
ies of hospitalized respiratory illness in Mali [17] and South 
Africa [18] have reported similar positivity for pneumococcal 
PCR on blood; 13.6% in Mali and 4%–6% among children aged 
<5 years in the South African study.
Findings from the extra sample set from Kilifi were consist-
ent with those of the PERCH study in similarly aged children, 
providing support for the PERCH results. Furthermore these 
data showed analogous findings in children aged 5–14  years 
and also provided results in neonates, a population not often 
studied.
In contrast with our findings, previous studies in Italy and 
South Africa observed 100% specificity of the whole-blood lytA 
PCR assay despite half the children being colonized with pneu-
mococcus, but these were much smaller studies (n = 147 and 
n = 100) and the study populations had important differences 
from PERCH [4, 10]. Controls in those studies were not a ran-
dom selection from the community but were attending hospital 
for allergies or celiac disease [4] or had previously been vacci-
nated with PCV-9 in a clinical trial [10], were older (mean age 
of approximately 5 years), had lower prevalence (50%) [4, 10] 
and density [4] of nasopharyngeal pneumococcal carriage, and 
possibly had higher socioeconomic status. The South African 
study also used serum rather than whole blood [10]. In Slovenia, 
pneumococcal PCR was positive from plasma in 2 of 29 (6.9%) 
children with a nonpneumonia acute febrile illness for which a 
nonpneumococcal cause was identified [19]. Both of the chil-
dren who tested positive were colonized with pneumococcus.
A review of older studies using a variety of gene targets to diag-
nose pneumococcal bacteremia from blood samples carried out 
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during the period 1993–2009 describes sensitivity of 57%–66% 
and specificity of 88%–99% [20]. The South African respiratory 
illness study also reported positivity of 61% among blood cul-
ture–positive cases [18]. Poor sensitivity has been thought to be 
due to low specimen volume used by nucleic acid amplification 
tests, PCR inhibitors, and pneumococcal autolysis and DNA 
degradation from suboptimal storage conditions [8, 9, 21]. lytA 
has been shown to be a specific gene target for identifying pneu-
mococcus for PCR assays [9, 21–24], and although the autolysin 
gene has been found in some Streptococcus pseudopneumoniae 
[25] and Streptococcus mitis genomes [7], it can be differenti-
ated from the lytA gene in S. pneumoniae [22, 25]. The pneu-
mococcal PCR method we used was published by the CDC in 
2007 [9] and is in widespread use globally, so it is possible that 
other investigators have also used the assay in control groups 
and not published the results, perhaps assuming that there was 
laboratory error. However, the PERCH study used 7 different 
laboratories and found positive controls at every site.
We carefully examined the performance of the PCR assay on 
whole blood. We included all positive amplification curves up 
Table 2. Characteristics Associated With Whole-Blood Pneumococcal Polymerase Chain Reaction Positivity Among General Pediatric Admissions to 
Kilifi County Hospital, Aged <60 Months
Children Aged 1–59 Months
Characteristic
All Cases
All Cases Aged 
0–28 days
Children With 
Pneumococcal 
Bacteremiaa
Children Without Pneumococcal Bacteremiaa
With Severe or Very 
Severe Pneumoniab
Without Severe 
or Very Severe 
Pneumonia b,c
Confirmed for 
Another Pathogend
WB+ n/N (%) WB+ n/N (%) WB+ n/N (%) WB+ n/N (%) WB+ n/N (%) WB+ n/N (%)
Overall 206/5527 (3.7) 29/1379 (2.1) 26/45 (57.8) 49/1173 (4.2) 47/1760 (2.7) 4/84 (4.8)
Age P = .002 … P = .25 P = .82 P = .60 P > .99
 0–28 d 29/1379 (2.1) 29/1379 (2.1) NA NA NA NA
 29 d < 6 mo 31/781 (4.0) NA 2/2 (100) 15/409 (3.7) 6/179 (3.4) 1/21 (4.8)
 6–11 mo 38/790 (4.8) NA 5/9 (55.6) 15/296 (5.1) 11/337 (3.3) 1/22 (4.6)
 12–23 mo 40/1075 (3.7) NA 9/12 (75.0) 11/257 (4.3) 10/517 (1.9) 1/24 (4.2)
 24–59 mo 68/1502 (4.5) NA 10/22 (45.5) 8/211 (3.8) 20/727 (2.8) 1/17 (5.9)
Pneumonia syndrome P < .001 P = .06 P = .03 P = .73 … P = .59
 Severe 50/901 (5.6) 9/212 (4.3) 11/13 (84.6) 25/627 (4.0) NA 1/10 (10.0)
 Very severe 53/1169 (4.5) 6/313 (1.9) 9/15 (60.0) 24/546 (4.4) NA 1/22 (4.6)
 Neitherc 103/3455 (3.0) 14/853 (1.6) 6/17 (35.3) NA 47/1760 (2.7) 2/52 (3.9)
HIV-antibody positive P = .004 P = .39 P = .68 P = .51 P = .02 P = .46
 Yes 19/269 (7.1) 2/60 (3.3) 7/13 (53.9) 1/59 (1.7) 6/94 (6.4) 0/12 (0.0)
 No 168/4671 (3.6) 25/1149 (2.2) 17/28 (60.7) 44/1003 (4.4) 36/1473 (2.4) 4/57 (7.0)
NP culture or NP/OP PCR 
positive for pneumococcus
P = .003 P = .12 P = .41 P = .09 … …
 Yes 40/771 (5.2) 3/45 (6.7) 10/16 (62.5) 21/528 (4.0) NA 0/11 (0.0)
 No 4/304 (1.3) 1/84 (1.2) 0/1 (0.0) 2/175 (1.1) NA 0/4 (0.0)
NP/OP PCR positive for any viruse P = .49 P = .32 P > .99 P > .99 … …
 Yes 29/782 (3.7) 3/56 (5.4) 7/13 (53.9) 14/546 (2.6) NA 0/10 (0.0)
 No 4/179 (2.2) 1/70 (1.4) 1/1 (100) 1/69 (1.5) NA 0/1 (0.0)
CXR+f P < .001 … … P = .03 … …
 Yes 9/46 (19.6) NA 3/3 (100) 5/37 (13.5) NA 1/3 (33.3)
 No 11/238 (4.6) NA 0/0 (0) 9/204 (4.4) NA 0/5 (0.0)
Died in hospital P = .03 P = .95 P = .48 P = .48 P = .24 P = .63
 Yes 24/415 (5.8) 4/196 (2.0) 7/10 (70.0) 5/89 (5.6) 3/64 (4.7) 1/18 (5.6)
 No 182/5112 (3.6) 25/1183 (2.1) 19/35 (54.3) 44/1084 (4.1) 44/1969 (2.6) 3/66 (4.6)
P values obtained by chi-square or Fisher’s exact test for difference in whole blood pneumococcal PCR positivity by characteristic within each subgroup. Bold indicates P < .05.
Abbreviations: CXR, chest radiograph; HIV, human immunodeficiency virus; NA, not applicable; NP, nasopharyngeal; NP/OP, nasopharyngeal/oropharyngeal; PCR, polymerase chain reaction; 
WB, whole blood.
aPneumococcus isolated on blood culture specimen.
bChildren who did not have cerebrospinal fluid collected. No other pathogens were identified on blood culture.
cNot severe or very severe pneumonia syndrome includes children with any other medical cause of admission, including other respiratory illnesses. NP/OP swabs and CXRs were not 
obtained from these children.
dConfirmed for another pathogen by culture of blood or cerebrospinal fluid.
e Respiratory viruses tested by multiplex PCR include respiratory syncytial virus A and B; parainfluenza viruses 1, 2, 3, and 4; coronaviruses OC43, NL63, 229E, and HKU; human metapneu-
movirus A and B; human bocavirus; influenza viruses A, B, and C; parecho/enterovirus; cytomegalovirus; and adenovirus.
fCXR results were included where children with WHO severe or very severe pneumonia had a digitalized CXR and standardized reporting according to WHO methods. A greater number of 
CXR results became available after March 2012 when a mobile CXR unit was procured.
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to a cycle threshold value of 40 cycles. The lower limit of reliable 
detection was 100–500 copies/mL of whole blood. Because the 
median lytA concentration in blood was on the lower end of 
this range, at 180 copies/mL among controls and 280 copies/mL 
among nonconfirmed cases [26], we expect that there would 
have been more positives if the assay were more sensitive.
The PERCH study invested in laboratory quality assurance, 
with implementation of a standard operating procedure aimed 
at reducing the potential for intralaboratory contamination and 
an external quality assurance program. Positive samples from 
control subjects were a feature of all 7 laboratories testing sam-
ples in the PERCH project, and it seems very unlikely that false 
positives due to intralaboratory contamination could explain 
all of these data. Dagan and colleagues suggested that pneumo-
coccal DNA may be detectable in the bloodstream of healthy 
individuals who do not develop clinical disease from pneumo-
cocci which directly invaded the blood from the nasopharynx or 
which entered the bloodstream phagocytosed by lymphoid cells 
[5]. Although others have suggested that the positives among 
healthy controls in that study may have been due to the nonspec-
ificity of the ply target gene used, our findings confirm positivity 
in healthy individuals with the more specific lytA target gene.
If we suppose that positive pneumococcal PCR results 
among control groups are due to the real presence of pneu-
mococcal DNA in the bloodstream, then we must question 
our understanding of the pathophysiology of pneumococcal 
Table 3. Characteristics Associated With Whole-Blood Pneumococcal Polymerase Chain Reaction Positivity Among General Pediatric Admissions to 
Kilifi County Hospital, Aged ≥60 Months
Characteristic
All Cases
Children With Pneumococcal 
Bacteremiaa
Children Without Pneumococcal Bacteremiaa
With Severe or Very 
Severe Pneumoniab
Without Severe or Very 
Severe Pneumoniab,c
Confirmed for Another 
Pathogend
WB+ n/N (%) WB+ n/N (%) WB+ n/N (%) WB+ n/N (%) WB+ n/N (%)
Overall 68/1441 (4.7) 10/13 (76.9) 14/184 (7.6) 33/850 (3.9) 2/24 (8.3)
Age P = .80 P = .18 P = .39 P = .59 P = .37
 5–7 y 37/800 (4.6) 5/5 (100) 7/88 (8.0) 20/443 (4.5) 1/12 (8.3)
 8–10 y 19/426 (4.5) 4/5 (80.0) 3/64 (4.7) 8/264 (3.0) 0/9 (0.0)
 11–14 y 12/215 (5.6) 1/3 (33.3) 4/32 (12.5) 5/143 (3.5) 1/3 (33.3)
Pneumonia syndrome P = .02 P > .99 P > .99 … P > .99
 Severe 6/71 (8.5) 1/1 (100) 5/65 (7.7) NA 0/2 (0.0)
 Very severe 15/188 (8.0) 5/6 (83.3) 9/119 (7.6) NA 0/6 (0.0)
 Neitherc 47/1180 (4.0) 4/6 (66.7) NA 33/850 (3.9) 2/16 (12.5)
HIV-antibody positive P = .001 P > .99 P = .06 P = .43 P = .40
 Yes 13/116 (11.2) 2/2 (100) 6/38 (15.8) 3/51 (5.9) 1/5 (20.0)
 No 49/1184 (4.1) 7/9 (77.8) 8/130 (6.2) 26/717 (3.6) 1/18 (5.6)
NP culture or NP/OP PCR 
positive for pneumococcus
P = .06 … P = .42 … …
 Yes 11/115 (9.6) 5/5 (100) 6/74 (8.1) NA 0/4 (0.0)
 No 1/60 (1.7) 0/0 (0) 1/39 (2.6) NA 0/2 (0.0)
NP/OP PCR positive for any 
viruse
P = .53 … P > .99 … …
 Yes 5/94 (5.3) 1/1 (100) 4/61 (6.6) NA 0/3 (0.0)
 No 6/69 (8.7) 3/3 (100) 3/44 (6.8) NA 0/2 (0.0)
CXR+f P = .02 … … … …
 Yes 3/14 (21.4) 3/3 (100) 0/9 (0.0) NA 0/1 (0.0)
 No 0/38 (0.0) 0/0 (0) 0/22 (0.0) NA 0/2 (0.0)
Died in hospital P > .99 P > .99 P = .69 P = .64 P > .99
 Yes 3/77 (3.9) 1/1 (100) 2/23 (8.7) 0/34 (0.0) 0/4 (0.0)
 No 65/1364 (4.8) 9/12 (75.0) 12/161 (7.5) 33/816 (4.0) 2/20 (10.0)
P values obtained by chi-square or Fisher’s exact test for difference in whole blood pneumococcal PCR positivity by characteristic within each subgroup. Bold indicates P < .05.
Abbreviations: CXR, chest radiograph; HIV, human immunodeficiency virus; NA, not applicable; NP, nasopharyngeal; NP/OP, nasopharyngeal/oropharyngeal; PCR, polymerase chain reaction; 
WB, whole blood.
aPneumococcus isolated on blood culture specimen.
bChildren who did not have cerebrospinal fluid collected. No other pathogens were identified on blood culture.
cChildren without severe or very severe pneumonia syndrome had any other medical cause of admission, including other respiratory illnesses. NP/OP swabs and CXRs were not obtained 
from these children.
dConfirmed for another pathogen by culture of blood or cerebrospinal fluid.
eRespiratory viruses tested by multiplex PCR include respiratory syncytial virus A and B; parainfluenza viruses 1, 2, 3, and 4; coronaviruses OC43, NL63, 229E, and HKU; human metapneu-
movirus A and B; human bocavirus; influenza viruses A, B, and C; parecho/enterovirus; cytomegalovirus; and adenovirus.
fCXR results were included where children with WHO severe or very severe pneumonia had a digitalized CXR and standardized reporting according to WHO methods. A greater number of 
CXR results became available after March 2012 when a mobile CXR unit was procured.
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disease. Blood pneumococcal PCR positivity among controls 
was higher among those with nasopharyngeal carriage (5.9% 
vs 3.7%; P  =  .02): perhaps pneumococci invade through the 
mucosa of the nasopharynx regularly enough to explain our 
findings among controls. We could be detecting killed organ-
isms within phagocytes and pneumococci processed for pres-
entation to the immune system by antigen-presenting cells. It 
may be that blood stream invasion is relatively common in chil-
dren but is normally eliminated by the immune system. In this 
model, invasive disease would only occur in the rare event that 
the immune system was unable to contain the infection. The 
high pneumococcal PCR positivity among children confirmed 
for bacterial pathogens other than pneumococcus suggests that 
illness itself might predispose to pneumococcal invasion from 
the nasopharynx or that pneumococcus acts as a copathogen.
The pneumococcal PCR assay in blood is not 100% specific 
in the diagnosis of pneumococcal pneumonia in all popula-
tions and should not be used as a diagnostic assay for clinical 
care without careful examination of test parameters, popula-
tion by population. For the PERCH project, setting a quanti-
tative threshold for positivity may be beneficial in predicting 
pneumococcal pneumonia. More work is needed to examine 
what happens when pneumococci breach the nasopharyngeal 
mucosa, how often this occurs, and potential host differences 
in handling such invasion events between different human 
populations. Although it is important to understand the patho-
physiology, the fact remains that pneumococcal PCR on blood 
specimens is nonspecific in the diagnosis of pneumococcal 
pneumonia in children in low- and middle-income countries.
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